Blue Circle Health is a new T1D health care delivery system focused on improving diabetes care in underserved communities. Our focus is to re-imagine the most complete level of care that can be provided to patients without the constraints that are currently present in US healthcare system. Began as a Board Observer in May 2023, and transitioned to a Board Director and Chief Financial Officer in October 2023.

Lead the Americas Business (North America & LATAM Regions) for PTC Therapeutics, Inc, which was approximately a $350M net revenue business in 2023. Manage a rare disease business with current in-line brands Emflaza (deflazacort) for Duchenne Muscular Dystrophy (DMD), Translarna (ataluren) for Duchenne Muscular Dystrophy from a nonsense mutation, Tegsedi (inotersen) for Polyneuropathy of hATTR Amyloidosis, and Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome (FCS) & Familial Partial Lipodystrophy (FPL), and the launch of new innovation brands, including UPSTAZA (eladocagene exuparvovec) for AADC deficiency (ultra-orphan), and Sepiapterin for PKU.

Led a Worldwide Business Platform as the VP/General Manager, across all functions (Operations, R&D, Quality, Medical, HR, Regulatory, Marketing), including an innovation hub site in Andover, MA. Led Global Marketing across Diabetes Care, including central & regional/country marketers.• Managed the launch of new innovation brands in Advanced Diabetes Care and achieved $1.10B in revenue across DC (100% vs. goal), while also growing profitability/operating income before taxes (OIBT) in 2018.• Won the 2018 BD Chief Marketing Officer (CMO) Award, recognition for Strategic Marketing Excellence.

Led Global Marketing/GM of the AZ Diabetes Injectables Business (including Bydureon, Byetta, Symlin, MYALEPT, and Dapatide)• Achieved Exenatide Family sales of $919M in 2015, which was $93M ahead of goal (111% attainment).

Initially managed all insulin brands for the Sanofi Diabetes business, including Lantus, Apidra, and Glargine U300 (Toujeo) and having full P&L accountability. Responsibilities broadened in 11/2012 to include the diabetes portfolio beyond insulins (GLP-1s, iBG Star Blood Glucose Monitor, Lixisenatide, LixiLan) and business unit strategy, and BU business development. In 2014, focus shifted to Toujeo global launch readiness and U.S. go-to-market sales & marketing launch planning. Toujeo was Sanofi’s #1 corporate priority globally.• Doubled revenue (net sales) in 3 years (2011 – 2014) from $3B to $6B with a late life-cycle portfolio.

Led the Allergy Business Unit including Allegra, Nasacort AQ, and XYZAL. In-licensed Auvi-Q from Intelliject (now Kaleo) and acquired the consumer goods company Chattem to switch Allegra from Rx-to-OTC in 3/2011. Served as the General Manager of the XYZAL Alliance (Sanofi & UCB Pharma).•. Exceeded all financial goals (>100% of goal) in 2009 ($723M net sales), 2010, and 2011 and Allegra OTC become the #2 OTC non-sedating antihistamine ahead of Zyrtec in its first year of launch.•. Led the Allergy Sales Team of 67 (60 Sales Professionals, 6 DSMs, & 1 RSD) for Allegra OTC.•. Led the Sanofi & UCB Pharma Alliance as the Alliance General Manager for XYZAL.In June 2010, responsibilities increased to also include Business Unit Leader of all Dermatology brands including Sculptra Aesthetics, Benzaclin Family, Carac, and many other therapeutic brands (in addition to my responsibilities of leading the Allergy Business Unit).•. Led the Dermik Sales Team of 144 (88 on the Aesthetic Sales Team, 56 on the Therapeutics Sales Team, and 10 home office employees including marketing, sales operations, research and analytics).

Led all commercial efforts for the Sanofi & UCB Pharma Alliance for the launch of XYZAL.• Surpassed launch goals: $24M vs. $18M, 191K TRxs vs. 106K TRx goal (launched October 2007), and doubled the share objective (2.3% vs. 1.1%).